The Sensidose AB technology is thus based on the preparation and intake of a specific and adjustable dose in small subunits (normally microtablets). The technology further incorporates the use of a counting device, termed the ‘dose automate`that allows for physicians, medical practitioners and patients to individualize doses to meet the specific requirements of the patient.
The technology has been granted patents in the U.S., Europe , China, Brazil, Mexico, Australia and other countries. The patent deals both with a method and a device for fine-tuning of individual patient dosages by counting variable numbers of standard partial doses ( e.g. micro-tablets). The patent is not limited to any specific tablet type or therapeutic indication. Thus, without the present invention, it is not possible, in a simple or effective manner, to obtain individual dosing for oral, solid dosage form medicines.
Sensidose AB is seeking partnerships with interested pharmaceutical companies to develop the PD market and others, and to exploit this technology on a worldwide basis.